- Details
- Description
-
Packaging Size24t/Boxt
-
Strength5mg
-
CompositonChidamide (Tucidinostat)
-
TreatmentRefractory peripheral T cell lymphoma (PTCL), T-cell leukemia-lymphoma (ATLL)
-
FormTablet
-
Brand爱谱沙(Epidaza)
-
Quantity Unit5mg*24t/Box
-
ManufacturerChipscreen Bioscences,Ltd.,china
Chidamide (also named Tucidinostat) is a histone deacetylase (HDAC) inhibitor that is used to treat various cancers, including relapsed or refractory peripheral T cell lymphoma (PTCL) and pancreatic cancer:
- Chidamide sold under the brand name 爱谱沙(Epidaza)® in china.
- Tucidinostat sold under the brand name Hiyasta ® in Japan.
Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan.
In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021.